Navigation Links
Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins
Date:10/31/2013

economic or regulatory environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological developments in the healthcare and life sciences industry; and statements of assumptions underlying such statements.

While Perrigo and New Perrigo believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Perrigo's and New Perrigo's control. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur. Actual results may differ materially from Perrigo's and New Perrigo's current expectations depending upon a number of factors affecting Perrigo's business, New Perrigo's business, Elan's business and risks associated with acquisition transactions. These factors include, among others: the inherent uncertainty associated with financial projections; restructuring in connection with, and successful close of, the transactions contemplated by the Transaction Agreement; subsequent integration of the transactions contemplated by the Transaction Agreement and the ability to recognize the anticipated synergies and benefits of the transactions contemplated by the Transaction Agreement; the receipt of required regulatory approvals for the transactions contemplated by the Transaction Agreement (including the approval of antitrust authorities necessary to complete the transactions contemplated by the Transaction Agreement); access to available financing (including financing for the transactions contemplated by the Transaction Agreement) on a timely basis and on reasonable terms; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insuran
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Perrigo Company To Release First Quarter Fiscal Year 2014 Results On October 31, 2013
2. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue and Earnings
3. Perrigo Nutritionals Works with the American Academy of Pediatrics (AAP) on Infant Nutrition Educational Initiative
4. Perrigo Company Will Release Fourth Quarter And Fiscal Year 2013 Results On August 15, 2013
5. Perrigo Receives FDA Tentative Approval For Generic Equivalent To Prandin(R)
6. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
7. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
8. Perrigo Launches First-Ever Industry Marketing Campaign For Store Brand OTC Medications
9. Perrigo Reports Record Revenue and Adjusted Earnings
10. Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013
11. Perrigo Company To Present At The Barclays Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
(Date:10/20/2014)... 20, 2014 Norgine B.V. today ... low volume bowel preparation, NER1006, presented at the 79 ... of Gastroenterology (ACG), Philadelphia, PA , ... weight and co-primary endpoint of cleansing success. The study ... MOVIPREP ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Positive preclinical,data was presented by Nektar ... for its,lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which ... model of colorectal,cancer when co-administered with bevacizumab. ... (AACR) Annual Meeting 2008 in San Diego,California, ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... in patients with non-small cell lung cancer has ... multi-center, monotherapy,study of KOS-1584 in patients with measurable ... previously received only one prior,chemotherapy regimen. The primary ...
Cached Medicine Technology:Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 2Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 3Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 4Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 5Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 2Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 3Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 4
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... 2011 Studies show drinking V8 100% vegetable juice may be ... and may help them manage their weight two areas ... Guidelines for Americans. 1 A study conducted by ... drank one, 8-ounce glass of vegetable juice each day, as ...
... , THURSDAY, Feb. 3 (HealthDay News) -- Daily electronic ... doctors better understand the condition, a new study shows. ... digital assistant (PDA) device. The patients used their PDA ... issues three times a day for 30 days. ...
... DALLAS Feb. 3, 2011 UT Southwestern Medical ... a national network that conducts clinical trials aimed at ... 100 community treatment providers and academic medical centers throughout ... Institute on Drug Abuse,s Clinical Trials Network (CTN). The ...
... Feb. 2 (HealthDay News) -- Researchers report that DNA analysis ... rare vascular disease, along with its genetic cause. As ... England Journal of Medicine , the debilitating, painful and progressive ... the hands and feet of patients, and in the vascular ...
... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, ... can help predict a daughter,s chances of not only having ... attack, new research shows. "Our new study shows that ... said Dr. Amitava Banerjee, a clinical research associate at the ...
... for ways to see dangerous blood clots before they ... School of Medicine in St. Louis report that they ... visible to a new kind of X-ray technology. ... cardiologist at Barnes-Jewish Hospital, these nanoparticles will take the ...
Cached Medicine News:Health News:Research suggests V8 100% vegetable juice can help people meet key dietary guidelines 2Health News:Researchers lead search for better drug-addiction treatments 2Health News:Scientists Discover Rare Vascular Disease 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 3Health News:New nanoparticles make blood clots visible 2Health News:New nanoparticles make blood clots visible 3
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: